Zelapar

— THERAPEUTIC CATEGORIES —
  • Parkinsonism

Zelapar Generic Name & Formulations

General Description

Selegiline HCl 1.25mg; orally-disintegrating tabs; contains phenylalanine.

Pharmacological Class

MAO-B inhibitor.

How Supplied

Tabs—60

Zelapar Indications

Indications

Adjunct in Parkinson's disease in patients with deteriorating response to levodopa/carbidopa.

Zelapar Dosage and Administration

Adult

Take (without liquids) in the AM before breakfast; do not eat/drink within 5 minutes (before or after). Place tablet on tongue, do not swallow. ≥16yrs: 1.25mg once daily for at least 6 weeks; if needed, may increase to max 2.5mg once daily if tolerated. Mild-to-moderate hepatic disease: reduce to 1.25mg once daily. Do not exceed max dose. Not bioequivalent to other forms of selegiline.

Children

<16yrs: not established.

Zelapar Contraindications

Contraindications

During or within 2 weeks of opioids (eg, meperidine, tramadol, methadone), MAOIs (including linezolid). Concomitant St. John's wort, cyclobenzaprine, dextromethorphan.

Zelapar Boxed Warnings

Not Applicable

Zelapar Warnings/Precautions

Warnings/Precautions

Monitor for new onset or exacerbation of hypertension. Monitor for somnolence; discontinue if daytime sleepiness or episodes of falling asleep develops. Psychosis. Impulse control/compulsive behaviors; consider dose reduction or discontinue if intense urges develop. Avoid abrupt cessation. Phenylketonuria. Severe hepatic (Child-Pugh score >9) or renal (CrCl<30mL/min) impairment, ESRD: not recommended. Elderly (higher risk of orthostatic hypotension). Pregnancy. Nursing mothers: not recommended (during and for 7 days after the last dose).

Zelapar Pharmacokinetics

See Literature

Zelapar Interactions

Interactions

See Contraindications. Avoid sympathomimetics. Risk of serotonin syndrome with concomitant antidepressants, SSRIs, SNRIs, MAOIs; allow at least 14 days after discontinuing selegiline before starting an SSRI (eg, fluoxetine), SNRI, tricyclic, tetracyclic, or triazolopyridine antidepressant; allow 5 weeks after discontinuing fluoxetine before starting selegiline. Caution with CYP3A4 inducers (eg, phenobarbital, phenytoin, carbamazepine, nafcillin, rifampin). May be antagonized by dopamine antagonists (eg, antipsychotics, metoclopramide). Consider reducing concomitant levodopa/carbidopa dose if dyskinesia occurs. Caution with tyramine-containing food or drink.

Zelapar Adverse Reactions

Adverse Reactions

Constipation, skin disorders, vomiting, dizziness, dyskinesia, insomnia, dyspnea, myalgia, rash; orthostatic hypotension (usually transient), hypertension, hallucinations, somnolence, irritation of the buccal mucosa.

Zelapar Clinical Trials

See Literature

Zelapar Note

Not Applicable

Zelapar Patient Counseling

See Literature